16 March 2021 in Journal of Experimental Medicine
SAMD9L is an interferon-induced tumor suppressor implicated in a spectrum of multisystem disorders, including risk for myeloid malignancies and immune deficiency. We identified a heterozygous de novo frameshift variant in SAMD9L in an infant with B cell aplasia and clinical autoinflammatory features who died from respiratory failure with chronic rhinovirus infection. Autopsy demonstrated absent bone marrow and peripheral B cells as well as selective loss of Langerhans and Purkinje cells. The frameshift variant led to expression of a truncated protein with interferon treatment. This protein exhibited a gain-of-function phenotype, resulting in interference in global protein synthesis via inhibition of translational elongation. Using a mutational scan, we identified a region within SAMD9L where stop-gain variants trigger a similar translational arrest. SAMD9L variants that globally suppress translation had no effect or increased mRNA transcription. The complex-reported phenotype likely reflects lineage-dominant sensitivities to this translation block. Taken together, our findings indicate that interferon-triggered SAMD9L gain-of-function variants globally suppress translation.
1 June 2007 in Oncology Reports
To identify physiologically relevant WT1 transcriptional target genes in prostate cancer cells, we have established stably transfected LNCaP cell lines expressing either WT1(A), its mutant counterpart DDS(R384W), or vector control. Microarray analyses of these cells revealed that vascular endothelial growth factor (VEGF) was differentially expressed in the engineered lines. Regulation of VEGF by WT1 likely contributes to kidney angiogenesis during development and WT1 mutants such as DDS(R384W) are associated with the Denys-Drash syndrome (DDS), characterized by renal abnormalities. Recent mechanistic studies have demonstrated that the WT1(A) isoform binds VEGF promoter sequences and transcriptionally regulates VEGF reporter constructs. However, regulation of VEGF is complex, involving both transcriptional and post-transcriptional processes. This study examined the ability of hormone and Actinomycin D treatment to alter VEGF mRNA levels in stably transfected WT-LNCaP, DDS-LNCaP, or V-LNCaP prostate cancer cells. The rationale of this study was based on a previous finding that enhancement of VEGF expression in DDS-LNCaP cells occurred only in the presence of the androgen analog, R1881. One possible explanation for these results was that DDS-WT1 stabilized VEGF mRNA so that it accumulated to higher levels. This hypothesis was tested by treating engineered LNCaP cells with Actinomycin D (Act D) and then measuring VEGF mRNA levels by quantitative real-time PCR. The combined effects of WT1 or DDS(R384W) and hormone were tested in these message stability assays and also in transcription assays of transiently transfected LNCaP cells. The results indicated that DDS-WT1 is unable to regulate VEGF transcription or stabilize VEGF mRNA in LNCaP prostate cancer cells. However our observations are also consistent with wild-type WT1(A) having both transcriptional and post-transcriptional effects on VEGF mRNA levels in the presence of hormone. These studies of VEGF regulation by WT1 and dysregulation by DDS(R384W) suggest an important role for WT1 in both normal and tumor-related angiogenesis.
1 May 2016 in The Journal of Immunology
Genome wide association studies have linked SNPs in innate signaling programs to an increased risk for autoimmune disease. One SNP, rs1990760, within the IFIH1 viral sensor (leading to an A to T amino acid change at codon 946) is strongly associated with multiple autoimmune diseases including type 1 diabetes (T1D). The impact of this variant on viral sensing and autoimmune pathogenesis, however, has not yet been determined. Using an overexpression system, we demonstrate that IFIH1-A946T exhibits heightened basal and post-stimulation signaling and increased viral control. Consistent with this finding, primary PBMCs from healthy subjects expressing the variant exhibit heightened signaling. To study IFIH1-A946T in vivo, we generated a novel knock-in murine model. Both heterozygous and homozygous variant mice display enhanced basal Type I IFN mRNA expression and splenomegaly. Moreover, homozygous pups manifest an embryonic survival defect. Further, IFIH1-T946 mice exhibit increased frequency of STZ-induced T1D. Finally, intercross of IFIH1-T946 mice with animals expressing the T1D risk variant in PTPN22 lead to a synergistic increase in T1D development. Together, our data demonstrate that IFIH1-A946T alters antiviral signaling and strongly supports the model that increased Type I IFN production driven by the variant leads to an inflammatory state that promotes autoimmunity, particularly in association with other autoimmune risk alleles.